We are live on
!
Find out more
FC
Fairpointe Capital Portfolio holdings
AUM
$66.3M
1-Year Est. Return
101.32%
This Fund
S&P 500
This Quarter
Est. Return
+7.46%
1 Year Est. Return
+101.32%
3 Year Est. Return
+48.06%
5 Year Est. Return
+95.29%
10 Year Est. Return
–
AUM
$5.95B
AUM Growth
+$968M
(+19%)
Cap. Flow
+$572M
Cap. Flow
% of AUM
9.61%
Top 10 Holdings %
Top 10 Hldgs %
31.15%
Holding
77
New
5
Increased
36
Reduced
29
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Xylem
XYL
|
+$166M |
| 2 |
AGCO
AGCO
|
+$114M |
| 3 |
Raymond James Financial
RJF
|
+$105M |
| 4 |
CTXS
Citrix Systems Inc
CTXS
|
+$93.7M |
| 5 |
Wolfspeed
WOLF
|
+$49.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boston Scientific
BSX
|
+$93.9M |
| 2 |
MHFI
MCGRAW-HILL FINANCIAL INC COM
MHFI
|
+$31.8M |
| 3 |
LXK
Lexmark Intl Inc
LXK
|
+$23.1M |
| 4 |
BLC
BELO CORP SER A
BLC
|
+$22.8M |
| 5 |
CGG
CGG
CGG
|
+$18.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 28.24% |
| 2 | Industrials | 17.22% |
| 3 | Healthcare | 10.92% |
| 4 | Communication Services | 10.04% |
| 5 | Financials | 7.56% |
Similar funds
EFM
NI
UL
WSC
AGEC
CIA
FLSMF
OHS
Fairpointe Capital's Q3 2013 Portfolio in Review
As of Q3 2013, Fairpointe Capital held 77 positions worth $5.95B, up 19% from $4.98B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Fairpointe Capital deployed $572M of net new capital in Q3 2013, opening 5 new positions and adding to 36 existing holdings. Its largest new stake was Xylem: 6,216,702 shares worth $174M.
By sector, the portfolio is most concentrated in Technology at 28% of assets, up from 28% a quarter earlier, followed by Industrials and Healthcare.
On the sell side, the largest reduction was Boston Scientific, an estimated $93.9M trimmed.
- Fairpointe Capital's largest Q3 2013 buy was Xylem: 6,216,702 shares worth $174M.
- Fairpointe Capital added most to Wolfspeed in Q3 2013, an estimated $49.2M increase.
- Fairpointe Capital's biggest Q3 2013 reduction was Boston Scientific, cutting an estimated $93.9M.
- Fairpointe Capital fully exited Denbury Resources, Inc. in Q3 2013, selling an estimated $15.6M.
- Fairpointe Capital's ten largest holdings make up 31% of its $5.95B portfolio in Q3 2013.
- Fairpointe Capital opened 5 new positions and closed 2 in Q3 2013.
- Fairpointe Capital's portfolio value rose 19% quarter-over-quarter to $5.95B.
Based on Fairpointe Capital's 13F filing for Q3 2013, filed 12 Nov 2013.